PHRRF (PharmaTher Holdings) Research & Development: $0.31 Mil (TTM As of Feb. 2026)


What is PharmaTher Holdings Research & Development?

PharmaTher Holdings PHRRF +4.74% Research & Development is $0.31 Mil as of Feb. 2026. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. PharmaTher Holdings's Research & Development for the three months ended in Feb. 2026 was $0.01 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Feb. 2026 was $0.31 Mil.

PharmaTher Holdings  (OTCPK:PHRRF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

PharmaTher Holdings Research & Development Related Terms

PharmaTher Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for PharmaTher Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaTher Holdings Research & Development Chart

PharmaTher Holdings Annual Data
Trend May21 May22 May23 May24 May25
Research & Development
0.62 2.03 2.23 1.57 0.42

PharmaTher Holdings Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.18 0.11 0.01 0.01

PharmaTher Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.31 Mil mean?
PharmaTher Holdings (PHRRF) has a Research & Development of $0.31 Mil as of Feb. 2026. Research and development expense is the total cost for research and development activities. View historical data on PharmaTher Holdings and its competitors.
Is PharmaTher Holdings' Research & Development too high?
PharmaTher Holdings' current Research & Development is $0.31 Mil.
How does PharmaTher Holdings' Research & Development compare to VRTX and REGN?
PharmaTher Holdings' Research & Development of $0.31 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on PharmaTher Holdings and its competitors. PharmaTher Holdings's current Research & Development is $0.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaTher Holdings stock overvalued right now?
PharmaTher Holdings (PHRRF) has a current Research & Development of $0.31 Mil. The current Research & Development is $0.31 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For PharmaTher Holdings (PHRRF), the current Research & Development is $0.31 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaTher Holdings Business Description

Other Exchanges NCC0:GermanyPHRM:Canada
Address 82 Richmond Street East, Toronto, ON, CAN, M5C 1P1
PharmaTher Holdings Ltd is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals for FDA approval to treat mental health, neurological, and pain disorders. Its product pipeline includes Ketamine, KETABET, Microneedle Patch and others.